Survey
Results
Back to entire year results 
Consumers survey results of for 1 quarter of 2024 in category
Pharmaceuticals with no prescription: International pharmaceutical company (representative office of a foreign manufacturer)
Info The annual ratings by results of Consumers survey calculated as average arithmetic mean rank, obtained in each of 4 quarters of year.
 
 I quarter (january—march)
 
 II quarter (april—june)
 
 III quarter (july—september)
 
 IV quarter (october—december)
!
Support with your vote those who deserves the title of the Favorite of the Year – 2024!
→ Give your best choice! ←
1. Bayer Consumer Health Link 60.00% 5
 
2. Bionorica  40.00% 3.33
 
2. KRKA Link 40.00% 3.33
 
2. Teva  40.00% 3.33
 
5. Alvogen Link 20.00% 1.67
 
5. Berlin-Chemie Link 20.00% 1.67
 
5. Delta Medical Link 20.00% 1.67
 
5. Heel Link 20.00% 1.67
 
5. Johnson & Johnson Link 20.00% 1.67
 
5. Naturwaren (Naturprodukt Vega (Dr. Theiss Naturwaren GmbH))Link 20.00% 1.67
 
5. Sanofi Link 20.00% 1.67
 
View results of previous, 2023 year  Show all companies
Is the list of participants incomplete or inaccurate?
Some participant is not listed, or vise versa, it's necessary to remove the nominee which has gone out of market? Please inform the organizers of the survey about that!
Add
company		 Delete
company

Normed consumer's score are calculated by 5-score scale, accordingly to the methodic of the research.
Notice This rating reflects the current interim results of the study of public opinion as on 11/03/2024 12:29:49 and it’s not yet final.  Details…
Comments(0)
all in a row | positive | negative

No comments yet… Be the first to leave comment on this topic!

or
You may sign in using:
Enter with Facebook Enter with Google Enter with VK
Aye Nay
  

Achtung! Please be polite! Although that modertors of this web-portal are excessively democratic, any unethical, unqotable or just rude expressions, which abuse other visitors of this web site, can be deleted. Also will be deleted any spam and public comments with private phone numbers.